[{"orgOrder":0,"company":"Nexilico","sponsor":"Siolta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Nexilico","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexilico \/ Siolta Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nexilico \/ Siolta Therapeutics"},{"orgOrder":0,"company":"Vivtex","sponsor":"Orbis Medicines","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"nCycles","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Vivtex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivtex \/ Orbis Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Vivtex \/ Orbis Medicines"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"GentiBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GentiBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"GentiBio \/ Bristol Myers Squibb"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : The collaboration combines Nexilico's AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for the treatment approaches in infant health.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery Platform

                          Sponsor : Siolta Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs.

                          Product Name : nCycles

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : nCycles

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery Platform

                          Sponsor : Orbis Medicines

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 08, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery Platform

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $1,900.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD.

                          Product Name : BX003

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          June 28, 2022

                          Lead Product(s) : BX003

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery Platform

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank